Nobin Hage, Kothapalli Jyothinath, Jini Moji, Chauhan Sharat, Tato Yijum, Munikumar Manne
Department of Pathology, Tomo Riba Institute of Health and Medical Sciences, Naharlagun, Arunachal Pradesh, India.
Department of Anatomy, Tomo Riba Institute of Health and Medical Sciences, Naharlagun, Arunachal Pradesh, India.
Maedica (Bucur). 2023 Mar;18(1):88-95. doi: 10.26574/maedica.2023.18.1.88.
The assessment of novel coronavirus disease 2019 (COVID-19) antibodies is essential to understand the transmission dynamics of contagious disease. The proportion of the population who developed antibodies against the COVID-19 disease can be estimated through population-based serosurveys. This population based cross sectional serosurvey was designed to assess the seroprevalence of IgG and IgM antibodies of COVID-19 infection. A population based cross sectional serosurvey included 1031 residents of Itanagar Capital Complex region (ICR), Arunachal Pradesh, India, aged above five years. Anti-SARS-CoV-2 specific IgG and IgM antibody levels were analyzed by chemiluminescence immunoassay based serological tests. The overall seropositivity for SARS-CoV-2 IgG and IgM was 92.24% and 7.7%, respectively. The seropositivity of IgG and IgM was 97.68% and 2.32%, respectively, in subjects fully vaccinated with two doses, 97.22% and 13.88%, respectively, in those vaccinated with the first dose, and 80% and 11.33%, respectively, in non-vaccinated participants. In contrast to indigenous tribal participants (IgG 90.55% and IgM 8.88%), seroprevalence was high in non-tribal subjects (IgG 94.72% and IgM 6.84%). Age, ethnicity, and area showed a positive correlation, while vaccination status exhibited a negative correlation with IgG levels (Pearson's coefficient -0.535). This first monocentric serosurvey following the high rate of infection with Delta variant in ICR found a high seropositivity for IgG. Further state level serosurveys are needed to assess the infection status, immunological response and associated comorbidities of COVID-19 infection. Periodic vaccination campaigns and early administration of booster doses to the general public might be beneficial in preserving immunity and prevent illness.
对2019年新型冠状病毒病（COVID-19）抗体的评估对于了解传染病的传播动态至关重要。通过基于人群的血清学调查可以估计产生针对COVID-19疾病抗体的人群比例。这项基于人群的横断面血清学调查旨在评估COVID-19感染的IgG和IgM抗体的血清阳性率。一项基于人群的横断面血清学调查纳入了印度阿鲁纳恰尔邦伊塔那噶首府地区（ICR）1031名年龄在5岁以上的居民。通过基于化学发光免疫分析的血清学检测分析抗SARS-CoV-2特异性IgG和IgM抗体水平。SARS-CoV-2 IgG和IgM的总体血清阳性率分别为92.24%和7.7%。在完全接种两剂疫苗的受试者中，IgG和IgM的血清阳性率分别为97.68%和2.32%；在接种第一剂疫苗的受试者中，分别为97.22%和13.88%；在未接种疫苗的参与者中，分别为80%和11.33%。与本地部落参与者（IgG 90.55%，IgM 8.88%）相比，非部落受试者的血清阳性率较高（IgG 94.72%，IgM 6.84%）。年龄、种族和地区呈正相关，而疫苗接种状况与IgG水平呈负相关（Pearson系数-0.535）。在ICR地区Delta变异株感染率较高之后进行的这项首次单中心血清学调查发现IgG的血清阳性率很高。需要进一步开展全州范围的血清学调查，以评估COVID-19感染的感染状况、免疫反应和相关合并症。定期开展疫苗接种活动并尽早向公众接种加强针可能有助于维持免疫力并预防疾病。
